Navigation Links
/R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
Date:10/5/2009

Ticker Symbol: CUR

QUEBEC CITY, Oct. 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland. Lab21 will offer the Previstage(TM) GCC test as part of its oncology testing services, and patient samples will be processed in DiagnoCure's U.S. clinical laboratory.

"This new partnership is a key initial step in reaching out to the European market. Lab21 is a leading provider of state-of-the-art diagnostics and world class customer service. This new avenue will support the global growth for our Previstage(TM) GCC Colorectal Cancer Staging Test," stated John C. Schafer, President and CEO of DiagnoCure.

Terms of the agreement were not disclosed.

Each year, 36,400 people are diagnosed with colorectal cancer in the U.K. Of that number, about 9,600 will be considered free of metastases (stage I or II) following the surgery and may benefit from the more accurate staging offered by Previstage(TM) GCC.

Presentation at BioContact

On October 7th, John C. Schafer, President and CEO of DiagnoCure, will present an update of the Company's activities at BioContact 2009, a biopharmaceutical partnership symposium, held in Quebec City.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. A major study published in the February 18, 2009, edition of the Journal of the American Medical Association demonstrated that GCC, to which DiagnoCure owns exclusive worldwide diagnostic rights, is the strongest independent predictor of colorectal cancer recurrence. The Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(R) PCA3(TM) PCA3 in vitro assay, and in Canada. For more information, visit www.diagnocure.com.

About Lab21

Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies. The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 international countries and is focused on infectious diseases for the blood-banking market. The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalized medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease. Lab21's clinical reference laboratory and corporate office is based in Cambridge and has additional UK manufacturing sites in Newmarket, Bridport and Ipswich. It also has R&D operations in Cape Town, South Africa. The Company's investors include Merlin Biosciences, Nexus Medical Partners, Medicis Capital, Rowan Dartington and Kreos Capital. Website: www.lab21.com

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure Inc.


'/>"/>
SOURCE DiagnoCure Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
2. DiagnoCure to host Q2 2009 earnings conference call and webcast
3. DiagnoCure announces first quarter 2009 results
4. New website empowers colorectal cancer patients when discussing critical treatment decisions - DiagnoCure launches www.mypersonalcancerdiagnosis.com
5. DiagnoCure to Host Q1 2009 Earnings Conference Call and Webcast
6. Major study on DiagnoCures GCC biomarker published in Jama
7. DiagnoCure announces fourth quarter 2008 and year-end results
8. DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
9. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
10. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
11. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... CareSet Labs today is releasing ... measured in Part D Medicare data. The dataset, called PaPR (Providers and Prescribing ... faxes or paper. The PaPR (pronounced "paper") data set aggregates this information ...
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: